A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma

Sponsor
Hoffmann-La Roche
Study ID
NCT02093000
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.

Study Details

This prospective, open-label, single arm, non-interventional study will investigate the effectiveness of bevacizumab monotherapy in participants with lung adenocarcinoma who previously received 4 to 6 cycles of induction platinum doublet plus bevacizumab.

Key Dates

First listed
Mar 20, 2014
Start date
Nov 30, 2014
Status verified
Feb 2018
Primary completion
Jan 31, 2018
Completion
Jan 31, 2018

Study Design

Enrollment
201 participants (actual)

Arms

  • Arm: Bevacizumab
    Participants who have received the induction phase of 4-6 cycles of bevacizumab plus platinum doublet chemotherapy will be treated with bevacizumab as maintenance treatment, according to approved label and local reimbursement.

Primary Outcome Measure

Progression-Free Survival (PFS), Defined as Time From First Dose of Maintenance Avastin Treatment Until Disease progression or death from any cause [ Time Frame: Baseline up to 40 months ]

Related Studies